                         SEQUENCE LISTING

 
<<110>  The Regents of the University of Colorado, a body corporate
       Kastelowitz-Lieberman, Noah
       Yin, Hang
 
<120>  COMPOSITIONS, METHODS AND USES FOR NOVEL ANTICOAGULANTS IN THE 
       COAGULATION PATHWAY

<130>  466888.000030

<150>  62/025,570
<151>  2014-07-17


<160>  13    

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from C2BL3

<400>  1

Gly Gly Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala 
1               5                   10          


<210>  2
<211>  25
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from MARCKS

<400>  2

Lys Lys Lys Lys Lys Arg Phe Ser Phe Lys Lys Ser Phe Lys Leu Ser 
1               5                   10                  15      


Gly Phe Ser Phe Lys Lys Asn Lys Lys 
            20                  25  


<210>  3
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from Bradykinin

<400>  3

Gly Arg Pro Pro Gly Phe Ser Pro Phe Arg 
1               5                   10  


<210>  4
<211>  25
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from MARCKS

<400>  4

Lys Lys Lys Lys Lys Arg Ala Ser Ala Lys Lys Ser Ala Lys Leu Ser 
1               5                   10                  15      


Gly Ala Ser Ala Lys Lys Asn Lys Lys 
            20                  25  


<210>  5
<211>  25
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from MARCKS

<400>  5

Ala Ala Ala Ala Ala Ala Phe Ser Phe Ala Ala Ser Phe Ala Leu Ser 
1               5                   10                  15      


Gly Phe Ser Phe Ala Ala Asn Ala Ala 
            20                  25  


<210>  6
<211>  10
<212>  PRT
<213>  artificial

<220>
<223>  fragment of homo sapiens C2BL3

<400>  6

Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala 
1               5                   10  


<210>  7
<211>  14
<212>  PRT
<213>  artificial

<220>
<223>  synthetic precursor peptide derived from C2BL3


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is L-propargylglycine

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is epsilon-azido norleucine

<400>  7

Gly Gly Xaa Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala Xaa 
1               5                   10                  


<210>  8
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from Bradykinin


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is a epsilon-azidolysine

<400>  8

Xaa Gly Arg Pro Pro Gly Phe Ser Pro Phe Arg 
1               5                   10      


<210>  9
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from Bradykinin

<400>  9

Lys Gly Arg Pro Pro Gly Phe Ser Pro Phe Arg 
1               5                   10      


<210>  10
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  synthetic mutant peptide derived from Bradykinin


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is epsilon-azidolysine

<400>  10

Xaa Gly Ala Pro Pro Gly Phe Ser Pro Phe Ala 
1               5                   10      


<210>  11
<211>  11
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is epsilon-azidolysine

<400>  11

Xaa Gly Gly Pro Pro Arg Phe Arg Pro Phe Ser 
1               5                   10      


<210>  12
<211>  14
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from C2BL3


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is L-propargylglycine

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is epsilon-azido norleucine

<400>  12

Gly Gly Xaa Asp Tyr Asp Lys Asp Gly Lys Ile Asp Ala Xaa 
1               5                   10                  


<210>  13
<211>  14
<212>  PRT
<213>  artificial

<220>
<223>  synthetic peptide derived from C2BL3


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is a cyclic linker

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is a cyclic linker

<400>  13

Gly Gly Xaa Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala Xaa 
1               5                   10                  


